Feds sue pharmacy gatekeepers over high insulin costs
The Federal Trade Commission sued on Friday the three largest pharmaceutical intermediaries charged with negotiating drug prices on behalf of insurers, claiming they are illegally maximizing profits by steering patients to high-cost insulin products.
Caremark, Express Scripts, Optum and their GPOs created a rebate system that boosted PBM profits, FTC alleges.
The federal government is suing some big pharmacy benefit managers over a system of drug rebates that regulators say has made ...
The Federal Trade Commission said pharmacy benefit managers created a "perverse drug rebate system" that artificially ...
Ypsomed reports positive outcomes from a randomized trial of its closed-loop insulin delivery technology during type 1 ...
Sen. Mike Braun has a unique opportunity to hold Novo Nordisk accountable for discontinuing insulin drug Levemir.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback